These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia. Singla R, Al-Sharif N, Al-Sayegh MO, Osman MM, Shaikh MA. Int J Tuberc Lung Dis; 2002 Jul; 6(7):585-91. PubMed ID: 12102297 [Abstract] [Full Text] [Related]
7. Drug-resistant tuberculosis in Budapest. Fodor T, Vadász I, Lõrinczi I. Int J Tuberc Lung Dis; 1998 Sep; 2(9):732-5. PubMed ID: 9755927 [Abstract] [Full Text] [Related]
8. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Nolan CM, Goldberg SV. Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140 [Abstract] [Full Text] [Related]
9. [Simultaneous resistance to rifampicin and isoniazid in patients with pulmonary tuberculosis]. Ouedraogo M, Ouedraogo SM, Diagbouga S, Coulibaly G, Achi V, Domoua K, N'Dathz M, Yapi A. Rev Mal Respir; 2000 Apr; 17(2):477-80. PubMed ID: 10859766 [Abstract] [Full Text] [Related]
11. Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002. LoBue PA, Moser KS. Int J Tuberc Lung Dis; 2005 May; 9(5):501-6. PubMed ID: 15875920 [Abstract] [Full Text] [Related]
13. Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi: results of a drug resistance survey. Sanders M, Van Deun A, Ntakirutimana D, Masabo JP, Rukundo J, Rigouts L, Fissette K, Portaelst F. Int J Tuberc Lung Dis; 2006 Feb; 10(2):178-83. PubMed ID: 16499257 [Abstract] [Full Text] [Related]
14. Drug resistance to the first line of antitubercular regimen (a preliminary report). Varaiya A, Gogate A. Indian J Public Health; 1998 Feb; 42(4):126-30. PubMed ID: 10389525 [Abstract] [Full Text] [Related]
19. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance. Shamaei M, Marjani M, Chitsaz E, Kazempour M, Esmaeili M, Farnia P, Tabarsi P, Amiri MV, Mirsaeidi M, Mansouri D, Masjedi MR, Velayati AA. Int J Infect Dis; 2009 Sep; 13(5):e236-40. PubMed ID: 19285897 [Abstract] [Full Text] [Related]
20. Impact of country of origin on drug-resistant tuberculosis among foreign-born persons in British Columbia. Moniruzzaman A, Elwood RK, Schulzer M, FitzGerald JM. Int J Tuberc Lung Dis; 2006 Aug; 10(8):844-50. PubMed ID: 16898367 [Abstract] [Full Text] [Related] Page: [Next] [New Search]